| scholarly article | Q13442814 |
| P50 | author | Stuart Schreiber | Q906562 |
| Longqin Hu | Q51736154 | ||
| T.A. Lewis | Q67474605 | ||
| Ah-Ng Kong | Q88994223 | ||
| P2093 | author name string | Lin Chen | |
| Lili Wang | |||
| Yu Chen | |||
| Jian Shen | |||
| Ah-Ng Tony Kong | |||
| Benito Munoz | |||
| Sadagopan Magesh | |||
| Sivaraman Dandapani | |||
| Daigo Inoyama | |||
| Carol Khodier | |||
| Michelle Palmer | |||
| Stuart L. Schreiber | |||
| Thomas J. Emge | |||
| John E. Kerrigan | |||
| Lesa J. Beamer | |||
| P2860 | cites work | Anti-inflammatory Effect of a Cell-Penetrating Peptide Targeting the Nrf2/Keap1 Interaction | Q28384313 |
| Small Molecule Modulators of Keap1‐Nrf2‐ARE Pathway as Potential Preventive and Therapeutic Agents | Q28386244 | ||
| Discovery of Potent, Novel Nrf2 Inducers Via Quantum Modeling, Virtual Screening, and In Vitro Experimental Validation | Q30559467 | ||
| Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. | Q33733198 | ||
| Bardoxolone methyl and kidney function in CKD with type 2 diabetes | Q34194954 | ||
| A novel strategy to activate cytoprotective genes in the injured brain | Q34686666 | ||
| Bioavailability of Sulforaphane from Two Broccoli Sprout Beverages: Results of a Short-term, Cross-over Clinical Trial in Qidong, China | Q34790043 | ||
| Kinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using surface plasmon resonance | Q35555898 | ||
| The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress | Q35837805 | ||
| Optimization of fluorescently labeled Nrf2 peptide probes and the development of a fluorescence polarization assay for the discovery of inhibitors of Keap1-Nrf2 interaction. | Q35842879 | ||
| Chemical and molecular regulation of enzymes that detoxify carcinogens | Q36210195 | ||
| Nrf2 as a target for cancer chemoprevention | Q36212945 | ||
| Nrf2: a potential molecular target for cancer chemoprevention by natural compounds | Q36399767 | ||
| Chemopreventive promise of targeting the Nrf2 pathway | Q36794329 | ||
| Dual roles of Nrf2 in cancer | Q37119963 | ||
| The Nrf2/ARE pathway as a potential therapeutic target in neurodegenerative disease | Q37248671 | ||
| Targeting the Nrf2 pathway against cardiovascular disease | Q37521075 | ||
| The cytoprotective role of the Keap1-Nrf2 pathway | Q37848718 | ||
| Integrated synthetic, pharmacological, and computational investigation of cis-2-(3,5-dichlorophenylcarbamoyl)cyclohexanecarboxylic acid enantiomers as positive allosteric modulators of metabotropic glutamate receptor subtype 4. | Q39623558 | ||
| An alkaloid-mediated desymmetrization of meso-anhydrides via a nucleophilic ring opening with benzyl alcohol and its application in the synthesis of highly enantiomerically enriched β-amino acids | Q57404992 | ||
| Safety, Tolerance, and Metabolism of Broccoli Sprout Glucosinolates and Isothiocyanates: A Clinical Phase I Study | Q63433163 | ||
| Control of oxidative stress by the Keap1-Nrf2 pathway | Q83694391 | ||
| Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD | Q83917014 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | protein-protein interaction | Q896177 |
| P1104 | number of pages | 5 | |
| P304 | page(s) | 3039-3043 | |
| P577 | publication date | 2013-03-14 | |
| P1433 | published in | Bioorganic & Medicinal Chemistry Letters | Q2709483 |
| P1476 | title | Discovery of a small-molecule inhibitor and cellular probe of Keap1-Nrf2 protein-protein interaction | |
| Discovery of a small-molecule inhibitor and cellular probe of Keap1–Nrf2 protein–protein interaction | |||
| P478 | volume | 23 |
| Q39953670 | A systematic molecular dynamics approach to the study of peptide Keap1-Nrf2 protein-protein interaction inhibitors and its application to p62 peptides |
| Q36463474 | Activation of NRF2 Signaling in HEK293 Cells by a First-in-Class Direct KEAP1-NRF2 Inhibitor |
| Q92511933 | Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development |
| Q38808418 | Application of Mass Spectrometry Profiling to Establish Brusatol as an Inhibitor of Global Protein Synthesis. |
| Q27689053 | Binding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complex |
| Q41914517 | Characterization of RA839, a Noncovalent Small Molecule Binder to Keap1 and Selective Activator of Nrf2 Signaling |
| Q34974952 | Chemical library screening for WNK signalling inhibitors using fluorescence correlation spectroscopy. |
| Q59620601 | Computer-Aided Design and Synthesis of 1-{4-[(3,4-Dihydroxybenzylidene)amino]phenyl}-5-oxopyrrolidine-3-carboxylic Acid as an Nrf2 Enhancer |
| Q90405814 | Construction of a novel quinoxaline as a new class of Nrf2 activator |
| Q57069735 | Design and development of Nrf2 modulators for cancer chemoprevention and therapy: a review |
| Q41897701 | Development of a steady-state FRET-based assay to identify inhibitors of the Keap1-Nrf2 protein-protein interaction |
| Q35814106 | Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway |
| Q28085561 | Discovery of direct inhibitors of Keap1-Nrf2 protein-protein interaction as potential therapeutic and preventive agents |
| Q48774191 | Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs. |
| Q41858529 | Identification of novel Nrf2 activators from Cinnamomum chartophyllum H.W. Li and their potential application of preventing oxidative insults in human lung epithelial cells |
| Q64892205 | Identification of novel indole derivatives acting as inhibitors of the Keap1-Nrf2 interaction. |
| Q41660762 | Metabolic and Homeostatic Changes in Seizures and Acquired Epilepsy-Mitochondria, Calcium Dynamics and Reactive Oxygen Species |
| Q58555577 | Mitochondrial protective effect of neferine through the modulation of Nrf2 signalling in ischemic stroke |
| Q89174376 | Modified Peptide Inhibitors of the Keap1-Nrf2 Protein-Protein Interaction Incorporating Unnatural Amino Acids |
| Q40709652 | Multiple binding modes of a small molecule to human Keap1 revealed by X-ray crystallography and molecular dynamics simulation. |
| Q37170555 | NAD(P)H:quinone oxidoreductase 1 inducer activity of some novel anilinoquinazoline derivatives |
| Q89765510 | NRF2-targeted therapeutics: New targets and modes of NRF2 regulation |
| Q41980350 | New strategies to inhibit KEAP1 and the Cul3-based E3 ubiquitin ligases. |
| Q90468452 | Nitric Oxide Engages an Anti-inflammatory Feedback Loop Mediated by Peroxiredoxin 5 in Phagocytes |
| Q36277241 | Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway |
| Q28077181 | Nrf2 Is an Attractive Therapeutic Target for Retinal Diseases |
| Q28066915 | Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad |
| Q38187867 | Overview of Recent Progress in Protein-Expression Technologies for Small-Molecule Screening |
| Q57165448 | Phenethyl Isothiocyanate, a Dual Activator of Transcription Factors NRF2 and HSF1 |
| Q41064004 | Polar Recognition Group Study of Keap1-Nrf2 Protein-Protein Interaction Inhibitors |
| Q89920945 | Potential Applications of NRF2 Modulators in Cancer Therapy |
| Q64958695 | Practical and Efficient Synthesis of α-Aminophosphonic Acids Containing 1,2,3,4-Tetrahydroquinoline or 1,2,3,4-Tetrahydroisoquinoline Heterocycles. |
| Q36144939 | Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators. |
| Q35824701 | Protein-protein interactions as drug targets |
| Q99616637 | Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials |
| Q47100134 | Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate |
| Q39270529 | Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016). |
| Q38125196 | S6K2: The Neglected S6 Kinase Family Member |
| Q35981250 | Small molecules, big targets: drug discovery faces the protein-protein interaction challenge |
| Q35738960 | State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors |
| Q98467289 | Structural basis of the anti-ageing effects of polyphenolics: mitigation of oxidative stress |
| Q47327932 | Synthesis of Novel Nitrogen-Containing Heterocycle Bromophenols and Their Interaction with Keap1 Protein by Molecular Docking |
| Q38780171 | Synthesis, molecular modeling and NAD(P)H:quinone oxidoreductase 1 inducer activity of novel 2-phenylquinazolin-4-amine derivatives |
| Q34043797 | Targeting Cullin-RING E3 ubiquitin ligases for drug discovery: structure, assembly and small-molecule modulation |
| Q33659621 | The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases |
| Q38837451 | The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update |
| Q28395641 | The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders |
| Q38481021 | The emerging role of Nrf2 in mitochondrial function |
| Q58701352 | The mycosporine-like amino acids porphyra-334 and shinorine are antioxidants and direct antagonists of Keap1-Nrf2 binding |
| Q38889475 | The role of modulation of antioxidant enzyme systems in the treatment of neurodegenerative diseases |
| Q28818264 | The status of Nrf2-based therapeutics: current perspectives and future prospects |
| Q90893987 | Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases |
Search more.